“Ondek® is harnessing the unique properties of a common gut bacterium to re-balance the immune system and improve the management of allergy.”
Dr Barry Marshall
Nobel Laureate of Physiology or Medicine 2005 and Founder of Ondek®
An estimated 10-40% of people in the world suffer from allergic disorders. Following the increasing incidence of allergic asthma over the past 50 years, food allergies have emerged in the last 20 years as a second wave of the allergy epidemic. A high proportion of the increase in allergic diseases is in children.1
Ondek’s product ImmBALANCE® is being developed to reduce allergy in children
disease in later life.
1 Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M. The WAO White Book on Allergy (Update. 2013)
2 Mullins RJ, et al. The economic impact of allergic disease in Australia: not to be sneezed at. ASCIA/Access Economics Report, November 2007.
3 Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9-17.
4 Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135(4):956-63 e1